Feb 9 (Reuters) - The U.S. Food and Drug Administration said a television advertisement for Novo Nordisk's weight-loss pill ...
In recent months, Johnson & Johnson has massively upped its spending on television advertisements for immunology heavyweight Tremfya, with the brand ...
Earlier this year, a Super Bowl ad from Hims touted the benefits of its weight-loss medications but didn’t list any of their side effects or potential harms. FDA rules require advertisements to ...
The FDA requested that Novo take immediate action to address the violations, which could include ceasing all ads containing misleading claims about the pill.
Health and Me on MSN
Wegovy Pill: FDA Says The TV Ad By Novo Nordisk On Its Weight Loss Pills Are Misleading
FDA has flagged Novo Nordisk’s Wegovy obesity pill advertisement for making false and misleading claims, saying it exaggerates superiority, emotional benefits and downplays risks. The regulator warned ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) has pulled a television ad for its drug Amvuttra (vutrisiran) after the U.S. FDA determined the spot was misleading. Amvuttra is approved for two heart conditions ...
A batch of untitled letters posted on the FDA’s database in recent days takes aim at what the agency has termed “false or misleading” drug ads from the likes of Novo Nordisk, argenx and Sobi. Among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results